Friday, September 11, 2020 7:06:05 PM
I went into the Kaplan Meyer table and there was a lot of change between 40 and 45 months so I averaged the surviving fraction at 40 and 45 months and the surviving fraction was .315 and .274 respectively which when multiplied by the N of the experimental group came out to 68.3 averaged between the 40 and 45 month mark.So since you can’t have a .3 of a person I would say 68 alive at that interval between 40 to 45 months.
For the 60 month time. According to the Kaplan Meyer table there was .201 surviving fraction Which times 232 which was the N of the experimental arm equals 47.8 “people alive”. Therefore rounding that up gives you 48.
So I would say that your numbers are consistent with the Kaplan-Meier curve.
Also It was pointed out to me that In My seeking Alpha blog, I had had some miss spellings that I corrected, and when I edited the blog they pulled it down for review. So I don’t know if it’s going to be put back up. If it comes in with a different different link I will submit the new link.
For the 60 month time. According to the Kaplan Meyer table there was .201 surviving fraction Which times 232 which was the N of the experimental arm equals 47.8 “people alive”. Therefore rounding that up gives you 48.
So I would say that your numbers are consistent with the Kaplan-Meier curve.
Also It was pointed out to me that In My seeking Alpha blog, I had had some miss spellings that I corrected, and when I edited the blog they pulled it down for review. So I don’t know if it’s going to be put back up. If it comes in with a different different link I will submit the new link.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
